drugset / Trial / NCT05093959
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction
Phase 2
Completed
86 enrolled
Wake Forest University Health Sciences
National Institute on Aging (NIA) · collabUniversity of South Florida · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with preserved ejection fraction (HFpEF).
Timeline
- Start
- 2022-01-04
- Primary completion
- 2025-12-18
- Completion
- 2026-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metformin | Small molecule | 1500 mg | Oral |